🔍

PARKHOSPS - Park Medi World

📊 NSE: PARKHOSPS 🏢 Hospital 📅 Last Updated: 11/13/2025 15:25

📢 Recent Corporate Announcements

Park Medi World to Launch 350-Bed Panchkula Hospital and Expand Mohali Facility by 150 Beds

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 10 Mar 2026, 09:39 AM

Park Medi World Limited is significantly expanding its footprint in the Tricity region by launching a new multi-super specialty hospital in Panchkula and expanding its Mohali facility. The Panchkula hospital, expandable to 350 beds, will commence operations on March 29, 2026. Additionally, the company will add 150 beds to its existing 350-bed Mohali facility with an investment of Rs. 40 crores funded via internal accruals. These moves will establish the company as the largest private healthcare provider in the region with a total of 850 beds.

New Panchkula hospital with up to 350 beds to start operations on March 29, 2026.
Expansion of Mohali facility by 150 beds (total 500) to be completed within 18 months.
Investment of approximately Rs. 40 crores for Mohali expansion funded through internal accruals.
Consolidated Tricity capacity to reach 850 beds, creating the region's largest private network.
Group-wide target to reach 5,460 beds by March 2028 from the current 3,610 beds.

💡 Investors should monitor the occupancy ramp-up at the new Panchkula facility and the timely execution of the Mohali expansion as these will be key drivers for revenue growth. The use of internal accruals for expansion is a positive sign of financial health and cash flow generation.

Park Medi World to Add 500 Beds via New Panchkula Hospital and Mohali Expansion

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 10 Mar 2026, 09:37 AM

Park Medi World is significantly expanding its footprint in the Tricity region by launching a new multispecialty hospital in Panchkula on March 29, 2026. Additionally, the board has approved a 150-bed expansion at its Mohali facility, which currently operates at 73% capacity, bringing the total regional capacity to 850 beds. The Mohali expansion involves an investment of approximately Rs. 40 crores, which will be entirely funded through internal accruals. This strategic move is expected to make the company the largest private healthcare network in the Tricity area, focusing on high-margin tertiary and quaternary care.

Launch of Panchkula Hospital (up to 350 beds) scheduled for March 29, 2026
Expansion of Mohali Hospital by 150 beds, increasing its total capacity from 350 to 500 beds
Investment of Rs. 40 crores for Mohali expansion to be funded via internal accruals over 18 months
Consolidated Tricity capacity to reach 850 beds, establishing regional market leadership
Group-wide target to reach 5,460 beds by March 2028 from the current 3,610 beds

💡 Investors should monitor the successful commissioning of the Panchkula facility and the subsequent ramp-up in occupancy rates. The use of internal accruals for expansion is a positive sign of financial health and cash flow generation.

Park Medi World to Launch Panchkula Hospital & Expand Mohali Capacity to 850 Beds

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 10 Mar 2026, 09:36 AM

Park Medi World is significantly scaling its presence in the Tricity region by launching a new multispecialty hospital in Panchkula on March 29, 2026. The board also approved a 150-bed expansion at its Mohali subsidiary, increasing its capacity from 350 to 500 beds with a Rs. 40 crore investment. These developments will bring the company's total regional capacity to 850 beds, establishing it as the largest private healthcare network in the area. The expansion is strategically funded through internal accruals and targets high-margin quaternary care services.

New Panchkula hospital to commence operations on March 29, 2026, with capacity up to 350 beds.
Approved 150-bed expansion at Mohali facility, increasing total beds there to 500 within 18 months.
Consolidated Tricity region capacity to reach 850 beds, establishing regional market leadership.
Expansion cost of Rs. 40 crores for the Mohali unit to be funded entirely through internal accruals.
Strategic focus on high-acuity specialties including Oncology, Neurosciences, and Robotic Surgeries.

💡 This expansion strengthens the company's competitive moat in North India and is expected to drive long-term revenue growth through higher-margin specialty services. Investors should monitor the occupancy rates of the new Panchkula facility in the coming quarters.

Park Medi World to Host Virtual Investor Meeting on March 14, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Mar 2026, 12:33 PM

Park Medi World Limited (PARKHOSPS) has announced a virtual meeting with analysts and institutional investors scheduled for March 14, 2026. The session is organized by Divitiae Investments and will commence at 11:30 a.m. The company has explicitly stated that no unpublished price-sensitive information will be shared during the interaction. This is a standard investor relations activity aimed at maintaining transparency with the market.

Virtual investor meeting scheduled for March 14, 2026, at 11:30 a.m.
Session organized by Divitiae Investments for institutional investors and analysts.
Disclosure made in compliance with Regulation 30 of SEBI Listing Regulations.
Management confirms no unpublished price-sensitive information (UPSI) will be discussed.

💡 Investors should look for post-meeting transcripts or presentations on the company's website for any qualitative business updates. No immediate action is required as this is a routine corporate disclosure.

Park Medi World to Host Investor Meet and Facility Visit on March 09, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 03 Mar 2026, 03:17 PM

Park Medi World Limited (PARKHOSPS) has scheduled an interaction with analysts and institutional investors on March 09, 2026. The engagement will consist of a physical facility visit and include both group and one-on-one meeting formats. The company has explicitly stated that no unpublished price-sensitive information (UPSI) will be discussed during these sessions. This move is part of the company's routine investor relations activities to provide transparency regarding its operational infrastructure.

Investor and analyst meet scheduled for March 09, 2026.
The event includes a physical facility visit to provide operational insights.
Interaction format covers both group and one-on-one meetings with management.
Disclosure submitted under Regulation 30 of SEBI Listing Regulations.
Company confirms no unpublished price-sensitive information will be shared.

💡 Investors should watch for any post-event presentations or transcripts uploaded to the exchange for insights into the company's operational outlook. No immediate trading action is required based on this routine disclosure.

Park Medi World to Participate in Arihant Bharat Connect Conference on March 11, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Mar 2026, 02:58 PM

Park Medi World Limited (PARKHOSPS) has announced its participation in the Arihant Bharat Connect Conference – Rising Stars 2026. The meeting is scheduled for March 11, 2026, and will be conducted in a virtual group format. This interaction is part of the company's standard engagement with institutional investors and analysts. The management has explicitly stated that no unpublished price-sensitive information will be shared during the session.

Participation in Arihant Bharat Connect Conference – Rising Stars 2026 scheduled for March 11, 2026.
The meeting will be held via virtual mode in a group setting.
Organized by Arihant Capital to connect 'Rising Stars' with institutional investors.
Management confirms no unpublished price-sensitive information (UPSI) will be discussed.

💡 Investors should watch for any post-meeting presentations or transcripts uploaded to the exchange to gain insights into the company's future growth trajectory.

Park Medi World Extends Timeline for SVPD Healthcare Acquisition to March 31, 2026

🟡 NEUTRAL ⭐ 7/10

M&A 📅 26 Feb 2026, 05:23 PM

Park Medi World Limited has announced a timeline extension for the final phase of its acquisition of KP Institute of Medical Sciences (KPIMS), a 360-bed hospital in Agra. While the 100% stake acquisition of KPS Wellness Private Limited was completed in January 2026, the acquisition of the second target entity, SVPD Healthcare Private Limited, is now expected by March 31, 2026. This represents a one-month extension from the previous indicative deadline of February 28, 2026. The overall deal remains intact as part of the company's strategic expansion in the healthcare sector.

Acquisition of KP Institute of Medical Sciences (KPIMS) involves a 360-bed facility in Agra
100% stake in KPS Wellness Private Limited already successfully acquired on January 30, 2026
Completion deadline for 100% stake in SVPD Healthcare Private Limited extended to March 31, 2026
The acquisition was originally approved by the Board on December 19, 2025

💡 Investors should track the final closure of the SVPD Healthcare acquisition by March end to ensure the full integration of the 360-bed Agra facility. The delay is minor and does not currently signal any deal-breaking issues.

Park Medi World to Conduct Investor Roadshow in Mumbai on February 16-17, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Feb 2026, 01:35 PM

Park Medi World Limited (PARKHOSPS) has announced a two-day investor roadshow scheduled for February 16 and 17, 2026, in Mumbai. The company's management will participate in physical one-on-one or group meetings with various analysts and institutional investors. This initiative is part of the company's regular investor relations activities to maintain market engagement. The company has explicitly stated that no unpublished price sensitive information will be shared during these sessions.

Roadshow scheduled for February 16 and 17, 2026, in Mumbai.
Meetings will be conducted in physical mode, including one-on-one and group formats.
Disclosure filed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Management confirms that no unpublished price sensitive information (UPSI) will be discussed during the event.

💡 Investors should watch for any investor presentations or meeting transcripts that may be uploaded to the stock exchange following the roadshow for insights into the company's outlook. No immediate trading action is required based on this routine disclosure.

Park Medi World to Attend DAM Capital Investor Conference on March 23, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Feb 2026, 04:34 PM

Park Medi World Limited (PARKHOSPS) has announced its participation in the Hospitals & Diagnostics conference organized by DAM Capital. The event is scheduled for March 23, 2026, and will be held physically in Mumbai. The management will engage in both one-to-one and group meetings with institutional investors and analysts. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be discussed during these interactions.

Participation in DAM Capital Hospitals & Diagnostics conference on March 23, 2026
Meeting format includes both one-to-one and group sessions with institutional investors
Physical meeting venue set for Mumbai as per SEBI Regulation 30 disclosures
Management confirms no unpublished price sensitive information will be shared
Disclosure filed with BSE and NSE on February 9, 2026

💡 Investors should watch for any investor presentations or transcripts released after the conference for insights into the company's growth outlook. This is a routine investor relations event and does not require immediate portfolio changes.

Park Medi World to Participate in Dolat Capital Investor Conference on Feb 18

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 03 Feb 2026, 03:33 PM

Park Medi World Limited (PARKHOSPS) has scheduled a meeting with analysts and institutional investors for February 18, 2026. The management will participate in the 'Corporate Conference 2026: Decoding Growth Strategies' organized by Dolat Capital in Mumbai. This physical conference is a routine engagement to discuss the company's growth outlook with the investment community. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during the event.

Investor conference scheduled for February 18, 2026, in Mumbai.
Event organized by Dolat Capital titled 'Decoding Growth Strategies'.
Management participation will be in a physical conference format.
Disclosure made in compliance with Regulation 30 of SEBI Listing Regulations.

💡 Investors should monitor the company's website or exchange filings for any investor presentations released post-conference to understand the discussed growth strategies.

Park Medi World Q3 FY26: PAT Surges 40% to ₹1,968M; Bed Capacity to Reach 5,260 by FY28

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 02 Feb 2026, 10:02 AM

Park Medi World reported a robust performance for 9M FY26, with revenue growing 17% YoY to ₹12,189 million and PAT increasing 40% to ₹1,968 million. The company is executing an aggressive expansion strategy, aiming to increase its bed capacity from 3,250 to 5,260 by FY28 through a mix of greenfield and brownfield projects. Operational efficiency improved as ARPOB rose to ₹27,406 and occupancy reached 65% despite the addition of new beds. Management targets a long-term EBITDA margin of 27% and an ROCE of 21%.

9M FY26 Revenue grew 17% YoY to ₹12,189 million with an EBITDA margin of 26%.
Net Profit (PAT) for 9M FY26 surged 40% YoY to ₹1,968 million.
Bed capacity to expand by 660 beds in FY26 through projects in Agra and Panchkula, reaching 3,910 beds.
ARPOB improved to ₹27,406 from ₹25,500, while occupancy increased to 65% from 62% YoY.
Long-term guidance includes reaching 5,260 beds by FY28 with a target ROE of 23%.

💡 Investors should focus on the company's ability to maintain margins during the rapid ramp-up of 2,000+ additional beds over the next two years. The efficient capex model of ₹3.4 million per bed makes this a high-growth play in the North Indian healthcare sector.

Park Medi World Releases Q3 FY26 Earnings Conference Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Jan 2026, 05:23 PM

Park Medi World Limited has made the audio recording of its earnings conference call available to the public following the announcement of its Q3 FY26 results. The call, held on January 29, 2026, discussed the unaudited standalone and consolidated financial performance for the quarter and nine months ended December 31, 2025. This disclosure is a standard regulatory requirement under SEBI Listing Regulations to ensure transparency for all shareholders. Investors can access the management's commentary and Q&A session via the link provided on the company's website.

Earnings conference call conducted on January 29, 2026, for Q3 and 9M FY26 results.
Audio recording link officially shared via SEBI compliance filing.
Covers both standalone and consolidated financial performance metrics.
Management discussion focused on the period ending December 31, 2025.

💡 Investors should listen to the recording to understand management's outlook on hospital occupancy and expansion plans. This is a routine update and does not contain new financial data beyond what was already reported in the Q3 results.

Park Medi World Q3 Revenue Up 18% to ₹4,100 Mn; 9M PAT Surges 43% with Strategic Acquisitions

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 28 Jan 2026, 05:40 PM

Park Medi World reported a strong Q3 FY26 with revenue growing 17.76% YoY to ₹4,100 million and PAT increasing 15.78% to ₹528 million. The 9-month performance was particularly robust, with PAT surging 42.6% YoY to ₹1,968 million, supported by a 65% occupancy rate and improved operational efficiencies. The company aggressively expanded its footprint by acquiring KP Institute of Medical Sciences in Agra for ₹245 crore and Febris Hospital in Delhi. Management remains committed to a cluster-based expansion model, targeting a total capacity of 5,260 beds by March 2028.

Q3 FY26 Revenue increased 17.76% YoY to ₹4,100 Mn with EBITDA margins expanding to 24.25%.
9M FY26 PAT grew by 42.60% YoY to ₹1,968 Mn, driven by higher patient volumes and better case mix.
Acquired 360-bed KP Institute of Medical Sciences in Agra for ₹245 crore in an all-cash deal.
Average occupancy ratio improved to 65% in 9M FY26 from 62% in the previous year.
Current bed capacity stands at 3,250 with a clear roadmap to reach 5,260 beds by March 2028.

💡 The company's strong earnings growth and aggressive inorganic expansion into high-density urban catchments signal a positive growth trajectory. Investors should monitor the successful integration of the newly acquired Agra and Delhi assets to ensure margin stability.

Park Medi World Q3 Revenue Up 18% to ₹410 Cr; PAT Rises 16% with Strategic Acquisitions

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 28 Jan 2026, 02:46 PM

Park Medi World reported a strong Q3 FY26 with revenue growing 17.76% YoY to ₹4,100 million and PAT increasing 15.78% to ₹528 million. The company maintained healthy EBITDA margins at 24.25% while integrating new capacities. Strategic growth was highlighted by the ₹245 crore acquisition of KP Institute in Agra and Febris Hospital in Delhi, bringing current bed capacity to 3,250. The management is executing a cluster-based expansion strategy with a target of 5,260 beds by March 2028.

Q3 FY26 Revenue grew 17.76% YoY to ₹4,100 million; 9M FY26 PAT surged 42.6% to ₹1,968 million.
EBITDA margins improved to 24.25% in Q3 FY26 compared to 23.79% in the same quarter last year.
Acquired 360-bed KP Institute of Medical Sciences in Agra for ₹245 crore and 200-bed Febris Hospital in Delhi.
Average Revenue Per Occupied Bed (ARPOB) increased to ₹27,482 in Q3 FY26 from ₹26,206 in FY25.
Ambitious expansion roadmap to reach 5,260 beds by March 2028 from the current 3,250 beds.

💡 Investors should focus on the successful integration and occupancy ramp-up of the newly acquired Agra and Delhi hospitals. The company's aggressive inorganic growth strategy and improving ARPOB make it a strong contender in the North Indian healthcare space.

Park Medi World Q3 FY26 Revenue Up 18% YoY; PAT Grows 16% to ₹528 Mn

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 28 Jan 2026, 02:44 PM

Park Medi World reported a strong Q3 FY26 with revenue growing 18% YoY to ₹4,100 million and PAT increasing 16% to ₹528 million. The 9-month performance was even more robust, with PAT surging 43% YoY to ₹1,968 million, driven by improved occupancy of 65% and higher ARPOB of ₹27,406. The company is aggressively expanding its footprint, having recently acquired 560 beds through Febris Hospital and KPIMS. Management aims to reach a total capacity of 5,260 beds by March 2028, positioning the firm as a dominant player in North India.

Q3 FY26 revenue rose 18% YoY to ₹4,100 Mn; EBITDA grew 20% to ₹994 Mn.
9M FY26 PAT surged 43% YoY to ₹1,968 Mn with a net margin of 16%.
Average Revenue Per Occupied Bed (ARPOB) increased 7.4% YoY to ₹27,406 in 9M FY26.
Strategic acquisitions of Febris Hospital (Delhi) and KPIMS (Agra) added 560 beds to the network.
Targeting a total capacity of 5,260 beds by March 2028 from the current 3,250 beds.

💡 Investors should favor the strong operational metrics and aggressive inorganic expansion strategy. Monitor the integration of newly acquired hospitals and their impact on overall margins in the coming quarters.

View All PARKHOSPS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total operating income grew 13.16% YoY to INR 1,393 Cr in fiscal 2025 from INR 1,231 Cr in fiscal 2024. Revenue is well-diversified across specialties, with no single specialty accounting for more than 16% of total revenue in fiscal 2025.

Geographic Revenue Split

100% of revenue is generated from North India, with a presence in key cities including Delhi, Gurgaon, Noida, Mohali, Jaipur, Behror, Faridabad, Panipat, Karnal, Sonipat, Ambala, Patiala, and Bathinda.

Profitability Margins

Operating margins declined from 31% in fiscal 2023 to 26.8% in fiscal 2025 due to moderate occupancy in recently acquired hospitals. Reported PAT margin improved from 12.14% in fiscal 2024 to 15.45% in fiscal 2025.

EBITDA Margin

Operating margin stood at 26.8% in fiscal 2025, a decrease from 31% in fiscal 2023. This decline is attributed to the low absorption of fixed costs in new acquisitions in Patiala and Mohali and changes in accounting to IND AS.

Capital Expenditure

Planned capital expenditure of INR 150-200 Cr for fiscal 2026 to fund greenfield projects in Panchkula and brownfield expansions in Narela and Kanpur.

Credit Rating & Borrowing

Credit rating reaffirmed at 'Crisil A+/Stable' in November 2025. Sanctioned bank limits of INR 362 Cr were utilized at 25% on average through June 2025.

⚙️ Operational Drivers

Raw Materials

Medical consumables, surgical implants, and pharmaceutical drugs (specific % of total cost not disclosed).

Capacity Expansion

Current capacity of 3,250 beds across 14 hospitals; planned expansion to reach 5,260 beds by March 2028 through the addition of 2,010 beds via 7 hospitals under execution.

Manufacturing Efficiency

Average Revenue Per Occupied Bed (ARPOB) is healthy at approximately INR 26,000. Occupancy levels in recently acquired units remain a key monitorable for efficiency.

📈 Strategic Growth

Expected Growth Rate

22%

Growth Strategy

Growth will be achieved through a cluster-based model, expanding bed capacity from 3,250 to 5,260 by March 2028. This includes integrating 7 hospitals currently under execution and acquiring brownfield projects like the 250-bed Krishna Super-speciality Hospital for INR 40 Cr. Growth is also driven by improving occupancy in recently acquired units in Patiala and Mohali and maintaining a healthy ARPOB of INR 26,000.

Products & Services

Super-specialty clinical services including Cardiology, Neurology, Oncology, Orthopaedics, Gastroenterology, Critical Care, Nephrology, and Women & Child Health.

Brand Portfolio

Park Group of Hospitals, Park Medi World.

New Products/Services

Integration of 7 new hospitals adding 2,010 beds by 2028; acquisition of Krishna Super-speciality Hospital (250 beds) in Bathinda.

Market Expansion

Targeting North India regions including Panchkula, Narela, and Kanpur with a timeline to reach 5,260 beds by March 2028.

Market Share & Ranking

Ranked as North India’s 2nd largest hospital chain.

🌍 External Factors

Industry Trends

The North Indian healthcare market is shifting towards large multi-specialty chains that can offer metropolitan-grade care in regional hubs. Park Group is positioning itself to capture this by expanding into cities like Bathinda and Panchkula, leveraging technology-enabled ecosystems to improve clinical outcomes.

Competitive Landscape

Operates as the 2nd largest chain in North India, competing with other multi-specialty providers in the Delhi-NCR and Punjab regions.

Competitive Moat

The group's moat is its 30-year brand recall and the promoters' proven ability to turn brownfield acquisitions profitable quickly. This is sustainable because high capital intensity and specialized talent requirements create significant entry barriers, while the group's established presence in 14 locations provides a strong referral network.

Consumer Behavior

Increasing consumer demand for metropolitan-grade healthcare locally in regional and rural districts like Bathinda and Patiala.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by medical waste pollution norms, healthcare facility standards, and pricing regulations on essential medical supplies. Compliance is critical to avoid operational disruptions in its 14 multi-specialty hospitals.

⚠️ Risk Analysis

Key Uncertainties

The primary risk is the timely stabilization of the 2,010 new beds planned by 2028. If occupancy remains moderate, the operating margin could fall below 23%, which would reduce cash accruals below the expected INR 300-320 Cr level.

Geographic Concentration Risk

100% of revenue is derived from North India (Delhi, Haryana, Punjab, Rajasthan), making the group sensitive to regional economic shifts or regulatory changes in these specific states.

Technology Obsolescence Risk

The group is mitigating technology risks by investing in modern medical infrastructure, including modular OTs and automated laboratories, to ensure clinical excellence and maintain its INR 26,000 ARPOB.